Frontlight ResearchEarly access
CompletedPhase 1
Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
Key facts
- Who runs it
- Everest Medicines (China) Co.,Ltd.
- Where
- China19 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 31 people enrolled
- Started
- 15 May 2023
- Ended
- 27 Jul 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- EVER001
- Record updated
- 15 September 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Having clinical diagnosis of primary membranous nephropathy, as verified by biopsy
- Have positive anti-PLA2R autoantibody test results > 20 relative units (RU)/ml
- During screening at least one testing of proteinuria must be >3.5 g/24h
- Have nephrotic range proteinuria for at least 8 weeks prior to Day 1 and no improvement (<50% reduction) despite supportive therapy of ACE inhibitor or ARB unless contraindicated, for patients who have two tests of proteinuria during screening ≥8.0g/24h, the duration of nephrotic range proteinuria for at least 8 weeks is not required
Who cannot take part
- Have received: B-cell targeted therapy except rituximab at any time;Rituximab and the biosimilars within 2 years (participants with rituximab treatment between 1 and 2 years prior to Day 1 are eligible if there is documented evidence of B-cell repopulation to >90% of Lower Limits of Normal Range.); Cyclophosphamide or Chlorambucil within 180 days;other immunosuppressive/immunomodulatory agents within 90 days;greater than 30mg/day prednisone or equivalence within 30 days
- Non-primary membranous nephropathy or other condition affecting the kidney
- Uncontrolled hypertension
- Acute or chronic infection,including positivity of tuberculosis infection test
- Positive serology for TP,HIV, HBV, or HCV
- eGFR at screening < 45 mL/min/1.73m2 or kidney function not stable
- Serum albumin level at screening # 25g/l
- Lab testing abnormality as: WBC< 3000/mm³, Lymphocyte < 1000/ mm³, neutrophil <1500/mm³, Hb < 80g/L, Platelet count <100×10e9/ L, Prothrombin time>1.5×ULN, Activated partial thromboplastin time ≥1.5×ULN, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 1.5×ULN, alkaline phosphatase and bilirubin >1.5×ULN
- Judged by the investigator that the participant is unlikely to comply with study procedures, restrictions, and requirements
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases.
Read full original descriptionShow less
The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted disease is primary membranous nephropathy.
The 2 groups in the trial
- EVER001 100mgTreatment being tested
EVER001 100mg QD for 4 weeks, followed by EVER001 100mg BID for 32 weeks.
Treatment: EVER001
- EVER001 200mgTreatment being tested
EVER001 200mg BID for 36 weeks.
Treatment: EVER001
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1b/2 Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 In Participants With Selected Proteinuric Glomerular Diseases
- Record updated
- 15 September 2026